Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008;110(1):c15-23.
doi: 10.1159/000149239. Epub 2008 Jul 31.

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment

Alastair J Hutchison  1 , M Edwina Barnett, Rolfdieter Krause, Jonathan T C Kwan, Ghodrat A Siami; SPD405-309 Lanthanum Study Group
Collaborators, Affiliations
Clinical Trial

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment

Alastair J Hutchison et al. Nephron Clin Pract. 2008.

Erratum in

  • Nephron Clin Pract. 2008;110(1):c23

Abstract

Background/aims: Lanthanum carbonate (LC, FOSRENOL) is an effective phosphate binder for which tolerability and a safety profile have been reported in haemodialysis patients. Patients from previous studies entered a 2-year extension, enabling assessment of efficacy and safety for up to 6 years of LC monotherapy.

Methods: Patients from four previous trials entered this study.

Results: Ninety-three patients started the extension, with 22 entering a sixth year of LC treatment. Two-thirds of all patients received LC doses of 2,250 or 3,000 mg/day. Reductions in serum phosphate and calcium x phosphate product were maintained for up to 6 years. There were no new or unexpected adverse events (AEs), and no increase in the incidence of events with increasing treatment exposure. Over the complete duration of therapy, treatment-related AEs occurred in 25.8% of patients and were primarily gastrointestinal in nature. No clinically relevant changes in liver function tests were observed and there was no evidence of adverse effects on the liver, bone or the central nervous system.

Conclusions: LC monotherapy was effective and well tolerated for up to 6 years with no evidence of safety concerns or increased frequency of AEs.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Overview of study timelines feeding into the 2-year extension.
Fig. 2.
Fig. 2.
Mean (±SD) serum phosphate levels throughout treatment with lanthanum carbonate (n = number of patients in the study at specified month).
Fig. 3.
Fig. 3.
Mean (±SD) serum calcium × phosphate product levels throughout treatment with lanthanum carbonate (n = number of patients in the study at specified month).
Fig. 4.
Fig. 4.
Patients with treatment-related adverse events by year of lanthanum carbonate exposure.
See this image and copyright information in PMC

References

    1. National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201. - PubMed
    1. Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant. 2004;19(suppl 1):i19–i24. - PubMed
    1. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007;96:2818–2827. - PubMed
    1. Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant. 2005;20:775–782. - PubMed
    1. Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol. 2005;63:461–470. - PubMed

Publication types

MeSH terms